Want to see HK:1477 full AI Analyst Report?
Total Valuation
Ocumension Therapeutics has a market cap or net worth of HK$5.07B. The enterprise value is HK$5.69K.
Market CapHK$5.07B
Enterprise ValueHK$5.69K
Share Statistics
Ocumension Therapeutics has 836,331,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding836,331,900
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Ocumension Therapeutics’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -4.11%.
Return on Equity (ROE)-0.04
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-4.11%
Return on Capital Employed (ROCE)-0.04
Revenue Per Employee1.46M
Profits Per Employee-287.08K
Employee Count552
Asset Turnover0.20
Inventory Turnover6.93
Valuation Ratios
The current PE Ratio of Ocumension Therapeutics is ―. Ocumension Therapeutics’s PEG ratio is 0.68.
PE Ratio―
PS Ratio6.54
PB Ratio1.43
Price to Fair Value1.43
Price to FCF-14.66
Price to Operating Cash Flow-40.48
PEG Ratio0.68
Income Statement
In the last 12 months, Ocumension Therapeutics had revenue of 804.35M and earned -158.82M in profits. Earnings per share was -0.20.
Revenue804.35M
Gross Profit360.92M
Operating Income-160.20M
Pretax Income-158.47M
Net Income-158.82M
EBITDA-29.95M
Earnings Per Share (EPS)-0.20
Cash Flow
In the last 12 months, operating cash flow was -105.29M and capital expenditures -253.36M, giving a free cash flow of -358.65M billion.
Operating Cash Flow-105.29M
Free Cash Flow-358.65M
Free Cash Flow per Share-0.43
Dividends & Yields
Ocumension Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.31
52-Week Price Change-37.61%
50-Day Moving Average5.65
200-Day Moving Average7.24
Relative Strength Index (RSI)64.93
Average Volume (3m)3.41M
Important Dates
Ocumension Therapeutics upcoming earnings date is Aug 20, 2026, TBA (Confirmed).
Last Earnings DateMar 26, 2026
Next Earnings DateAug 20, 2026
Ex-Dividend Date―
Financial Position
Ocumension Therapeutics as a current ratio of 3.70, with Debt / Equity ratio of 5.10%
Current Ratio3.70
Quick Ratio3.46
Debt to Market Cap0.03
Net Debt to EBITDA7.18
Interest Coverage Ratio-67.26
Taxes
In the past 12 months, Ocumension Therapeutics has paid 350.00K in taxes.
Income Tax350.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Ocumension Therapeutics EV to EBITDA ratio is -168.40, with an EV/FCF ratio of -14.06.
EV to Sales6.27
EV to EBITDA-168.40
EV to Free Cash Flow-14.06
EV to Operating Cash Flow-47.90
Balance Sheet
Ocumension Therapeutics has HK$547.50M in cash and marketable securities with HK$187.62M in debt, giving a net cash position of HK$359.89M billion.
Cash & Marketable SecuritiesHK$547.50M
Total DebtHK$187.62M
Net CashHK$359.89M
Net Cash Per ShareHK$0.43
Tangible Book Value Per ShareHK$1.37
Margins
Gross margin is 44.87%, with operating margin of -19.92%, and net profit margin of -19.75%.
Gross Margin44.87%
Operating Margin-19.92%
Pretax Margin-19.70%
Net Profit Margin-19.75%
EBITDA Margin-3.72%
EBIT Margin-19.92%
Analyst Forecast
The average price target for Ocumension Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast93.26%
EPS Growth Forecast49.38%